The European Life Sciences Coalition

The European Life Sciences Coalition (ELSC) has been launched to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilising greater levels of private and public investment across the sector. Created in association with Invest Europe, the coalition brings together leading European life sciences venture capital firms, research institutions, and other stakeholders across the value chain.

ELSC members collectively manage more than €26 billion in Life Sciences-specific assets and have invested in, or helped found, over 1,500 life sciences and biotechnology companies. As hands-on investors and operators, coalition members bring practical, market-driven perspectives to policy discussions on capital allocation, company formation, and scale-up dynamics.

The creation of the ELSC responds to growing concern that, despite strong scientific foundations and entrepreneurial talent, Europe is increasingly unable to scale and retain its life sciences innovation. Structural barriers, including the underutilisation of private savings, fragmented capital markets, low (and decreasing) numbers of specialised VC firms, and slow and uneven regulatory processes, continue to limit access to growth capital and push promising companies to seek financing elsewhere.

Members of the European Life Sciences Coalition: Novo Holdings, Forbion, HealthCap, Omega Funds, Sofinnova Partners, VIB, Cooley (UK) LLP, Covington & Burling LLP, Van Lanschot Kempen, Andera Partners, BioInnovation Institute, 4BIO Capital, LifeScience Org, Angelini Ventures and Asabys.

The coalition saw a highly successful launch on February 12, 2026, receiving enthusiastic social and media coverage and strong industry support for its mission to revitalize the continent’s investment landscape. Please see below for a sample of the 70+ media articles coverage generated from the ELSC launch:

• FT

• SCRIP

• Fierce Biotech

• Firstword Pharma

• Spencer Riley

• BioSpace

• European Biotechnology

• Belga News

• Nordic Life Science

• The Times

• Nature.com